Entrada Therapeutics Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: $6.75 High: $7.53
on July 10, 2025

52 Week Range

Low: $6.59 High: $21.79
on July 1, 2025
on December 9, 2024

All-Time High: $36.85 on November 15, 2021

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $271.7M
EPS i N/A
P/E Ratio (TTM) i 12.34
Forward P/E i -2.27
P/B Ratio i 0.60
PEG Ratio i -2.27
Div. Yield i N/A
ROE i 7.22%
Beta i N/A
Debt to Equity i 13.66

Financial Highlights

Profitability

Gross Margin i N/A
Operating Margin i N/A
Profit Margin i N/A

Returns and Earnings

Return on Assets (TTM) i N/A
Return on Equity (TTM) i 7.22%
EBITDA i N/A
Net Income (TTM) i N/A

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i
Quarterly Revenue Growth i
Quarterly Earnings Growth i

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Entrada Therapeutics TRDA 271.75M Small-cap-6.50%-18.16%-13.89%-53.86%-61.28%-55.86%-30.17%-66.37%
Vertex VRTX 124.20B Large-cap4.33%6.20%0.85%17.08%18.18%-2.00%63.56%62.62%
Regeneron REGN 59.14B Large-cap2.27%6.92%2.45%-19.68%-21.73%-49.77%-9.05%-14.20%
Cg Oncology CGON 1.98B Small-cap0.78%-1.35%53.77%-10.23%-6.42%-23.64%-22.81%-22.81%
Belite Bio BLTE 1.94B Small-cap4.30%1.37%6.00%11.83%-4.22%30.51%52.51%105.64%
Disc Medicine IRON 1.93B Small-cap5.94%9.29%64.63%-2.09%-7.13%18.42%19.36%-82.16%

Ownership & Short Interest

Insider Ownership i 12.36%
Institutional Ownership i 80.10%
Shares Short i 1M
Short Ratio i 8.24
Short % of Shares Outstanding i 5.37%
Average 10-Day Volume i 173K
Average 90-Day Volume i 143K

Entrada Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Entrada Therapeutics would have performed over time.

$
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is TRDA's 52-week high and low?

In the last 52 weeks, Entrada Therapeutics reached a high of $21.79 (on December 9, 2024) and a low of $6.59 (on July 1, 2025).

What is the market cap and P/E ratio for TRDA?

Curious about Entrada Therapeutics's size and valuation? Its market capitalization stands at 271.75M. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.34, and the forward P/E (looking ahead) is -2.27.

Does TRDA pay dividends? If so, what's the yield?

As for dividends, Entrada Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Entrada Therapeutics's main competitors or similar companies to consider before investing?

When looking at Entrada Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Vertex
VRTX
124.20BHealthcareBiotechnology-2.00%63.56%
Regeneron
REGN
59.14BHealthcareBiotechnology-49.77%-9.05%
Cg Oncology
CGON
1.98BHealthcareBiotechnology-23.64%-22.81%
Belite Bio
BLTE
1.94BHealthcareBiotechnology30.51%52.51%
Disc Medicine
IRON
1.93BHealthcareBiotechnology18.42%19.36%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Entrada Therapeutics Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Entrada Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.22%, the Debt to Equity ratio from the most recent quarter is 13.66, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for TRDA?

Looking at Entrada Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $172M. Compared to the same quarter last year (YoY), quarterly revenue grew by -65.20%, and quarterly earnings saw a YoY growth of -65.23%.

How much of TRDA stock is held by insiders and institutions?

Wondering who owns Entrada Therapeutics stock? Company insiders (like executives and directors) hold about 12.36% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.10%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.